Oral HRS-7535 Lowered A1c in Trial
Nonpeptide oral agent requires no fasting administration.
-
By
-
Kathryn Wighton
-
June 5, 2026
-
Clinical Scorecard: Oral HRS-7535 Lowered A1c in Trial
At a Glance
| Category | Detail |
|---|
| Condition | Type 2 Diabetes |
| Key Mechanisms | Nonpeptide glucagon-like peptide-1 receptor agonist (GLP-1 RA) |
| Target Population | Patients aged 18 to 75 years with inadequately controlled type 2 diabetes on metformin |
| Care Setting | Phase 2 randomized controlled trial across 44 centers in China |
Key Highlights
- HRS-7535 reduced hemoglobin A1c levels compared to placebo after 16 weeks.
- Patients achieved hemoglobin A1c levels below 7.0% ranged from 49% to 63% in HRS-7535 groups versus 15% in placebo.
- Gastrointestinal adverse events were the most common treatment-related events, predominantly mild or moderate.
Guideline-Based Recommendations
Diagnosis
- Eligible patients had hemoglobin A1c levels of 7.5% to 11.0%.
Management
- HRS-7535 was administered once daily at doses of 15 mg, 30 mg, 60 mg, or 90 mg.
Monitoring & Follow-up
- Monitor hemoglobin A1c levels and gastrointestinal adverse events.
Risks
- Gastrointestinal adverse events occurred in 72% to 85% of patients receiving HRS-7535.
Patient & Prescribing Data
194 patients aged 18 to 75 years with type 2 diabetes inadequately controlled with metformin.
Rescue antihyperglycemic therapy was required in 3% to 8% of patients receiving HRS-7535 compared to 31% in placebo.
Clinical Best Practices
- Consider the patient's body mass index and demographics when interpreting trial results.
- Titrate doses carefully to manage gastrointestinal tolerability.
Related Resources & Content
